Clinical Validation of the AliveCor Kardia 12L and 6L Devices

NACompletedINTERVENTIONAL
Enrollment

221

Participants

Timeline

Start Date

September 27, 2021

Primary Completion Date

February 9, 2022

Study Completion Date

May 24, 2023

Conditions
Arrhythmia
Interventions
DEVICE

Kardia 12L

The purpose of this study is to collect clinical validation data to support an FDA submission for a 510(k) for the Kardia 12L hardware which enables the simultaneous diagnostic quality recording of all 6 limb leads and any chest lead. We will be recording both Leads V2 and V4 in a sequential fashion along with the Limb leads and a simultaneous 12-lead ECG to validate the hardware and a Deep Neural Network model which expands the 7 leads into a complete 12-lead ECG. The 12-lead ECG used for validation of the recordings and the 12-lead synthesis model is the GE Cardiosoft System which is FDA cleared.

Trial Locations (1)

73104

University of Oklahoma Health Sciences Center, Oklahoma City

All Listed Sponsors
lead

University of Oklahoma

OTHER

NCT05053243 - Clinical Validation of the AliveCor Kardia 12L and 6L Devices | Biotech Hunter | Biotech Hunter